Proteome Sciences (CHIX:PRML) Total Stockholders Equity: £-9.53 Mil (As of Dec. 2025)


What is Proteome Sciences Total Stockholders Equity?

Proteome Sciences CHIX:PRML +7.63% Total Stockholders Equity is £-9.53 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

Proteome Sciences's Total Stockholders Equity for the quarter that ended in Dec. 2025 was £-9.53 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Proteome Sciences's Book Value per Share for the quarter that ended in Dec. 2025 was £-0.03. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Proteome Sciences's Debt-to-Equity for the quarter that ended in Dec. 2025 was -1.65.

Proteome Sciences  (CHIX:PRMl) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Proteome Sciences's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-9.531-0)/295.182
=-0.03

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Proteome Sciences's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(14.946 + 0.824) / -9.531
=-1.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Proteome Sciences Total Stockholders Equity Related Terms

Proteome Sciences Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Proteome Sciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Proteome Sciences Total Stockholders Equity Chart

Proteome Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.78 -0.84 -3.07 -6.62 -9.53

Proteome Sciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.07 -5.27 -6.62 -8.58 -9.53
What does a Total Stockholders Equity of £-9.53 Mil mean?
Proteome Sciences (CHIX:PRML) has a Total Stockholders Equity of £-9.53 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Proteome Sciences and its competitors.
Is Proteome Sciences' Total Stockholders Equity too high?
Proteome Sciences' current Total Stockholders Equity is £-9.53 Mil.
How does Proteome Sciences' Total Stockholders Equity compare to TMO and DHR?
Proteome Sciences' Total Stockholders Equity of £-9.53 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Diagnostics & Research company?
A good Total Stockholders Equity depends on the Medical Diagnostics & Research industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Proteome Sciences and its competitors. Proteome Sciences's current Total Stockholders Equity is £-9.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteome Sciences stock overvalued right now?
Based on GuruFocus' analysis, Proteome Sciences (CHIX:PRML) is currently considered Modestly Undervalued. The stock's GF Value™ is £0.02, compared to a current price of £0.01 — trading 29.5% below its estimated fair value. The current Total Stockholders Equity is £-9.53 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Proteome Sciences (CHIX:PRML), the current Total Stockholders Equity is £-9.53 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Proteome Sciences Business Description

Other Exchanges PRM:UKPI2:Germany
Address Downside Bridge Road, Coveham House, Cobham, Surrey, GBR, KT11 3EP
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.